drugset / Trial / NCT00547248

Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines

NCT00547248

Phase 3 Completed 756 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this observer blind study is to assess the safety in terms of fever \>39°C (rectal temperature) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal vaccine GSK 1024850A at 12 to 18 months of age in children previously primed with the same vaccines including a pneumococcal conjugate vaccine co-administered with a diphtheria, tetanus, whole cell pertussis (DTPw)-combined vaccine and OPV or IPV vaccines. Subjects participating in this study should have received three doses of pneumococcal conjugate vaccine in the primary study. This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00344318)

Timeline

Start
2007-10-22
Primary completion
2008-05-10
Completion
2008-10-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prevnar 13 Vaccine Intramuscular
Subject Synflorix Vaccine Intramuscular
Background HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN Vaccine
Background Polio Sabin Vaccine Oral
Background Poliorix™ Vaccine Intramuscular
Background Tritanrix-HepB Vaccine Intramuscular